No Data
No Data
Argenica Therapeutics' Neuroprotective Drug ARG-007 Shows Positive Results in Ferret Preclinical Study
A preclinical study found that Argenica Therapeutics' (ASX:AGN) ARG-007 can significantly reduce damage to brain cells, providing further evidence of the potential of the neuroprotective drug as a tre
Argenica Therapeutics Price Target Cut 6.7% to A$1.40/Share by Euroz Hartleys
Argenica Therapeutics Price Target Cut 6.7% to A$1.40/Share by Euroz Hartleys
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial
Argenica Therapeutics (ASX:AGN) dosed the first batch of five patients for its phase two trial investigating the use of ARG-007 medication in patients with acute ischaemic stroke, according to a Wedne
Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%
Argenica Therapeutics (ASX:AGN) dosed the first patient for its phase two trial investigating the use of ARG-007 medication to treat patients with acute ischaemic stroke, according to a filing with th
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%
Biotechnology company Argenica Therapeutics (ASX:AGN) has been granted the rare pediatric disease designation by the US Food and Drug Administration for its neuroprotective drug ARG-007, which is used
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%
Argenica Therapeutics (ASX:AGN) concluded the manufacturing and release testing of GMP-grade ARG-007 drug product, intended to treat stroke patients, the biotechnology company said Monday. The ARG-007
No Data